13 Best Russell 2000 Stocks to Buy Right Now
On January 6, Royce Investment Partners released their outlook for the small-cap stocks in 2026.
Bridgebio Pharma Inc. (BBIO)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bayforest Capital Theodoros Tsagaris | 2,234 | $170,879 | 0.13% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.24 | 1,752 | $24,948.48 | 3,294 | 2021-12-29 | Filing | |
| $13.16 | 796 | $10,475.36 | 2,687 | 2021-12-28 | Filing | |
| $12.68 | 1,542 | $19,552.56 | 1,542 | 2021-12-28 | Filing | |
| $12.68 | 1,542 | $19,552.56 | 3,433 | 2021-12-28 | Filing | |
| $13.18 | 1,891 | $24,923.38 | 1,891 | 2021-12-28 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $78.10 | 1,855 | $144,881.99 | 4,518,447 | 2026-01-09 | Filing | |
| $77.46 | 10,677 | $827,015.86 | 4,520,302 | 2026-01-09 | Filing | |
| $76.53 | 6,067 | $464,289.31 | 4,530,979 | 2026-01-09 | Filing | |
| $75.61 | 1,401 | $105,927.93 | 4,537,046 | 2026-01-09 | Filing | |
| $78.19 | 375 | $29,322.00 | 715,686 | 2026-01-09 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,862,691 | $1,289,827,235 | 0.02% | |
| 2. | Ubs Group AgCALL | 3,863,500 | $295,519,115 | 0.05% |
| 3. | 1,875,665 | $143,469,616 | 0.02% | |
| 4. | 1,314,303 | $100,531,037 | 0.05% | |
| 5. | 86,250,000 | $97,078,905 | 0.77% |
News See All
Analysts Remain Positive on BridgeBio Pharma, Inc. (BBIO) After Strong 2025 Results
TheFly reported on January 8 that Truist raised its price target on BBIO to $86 from $80 while maintaining a Buy rating.
Top 10 Oncology Stocks to Buy Now
The oncology market in the United States was estimated at $81.34 billion in 2025 and is expected to reach $211.78 billion by 2034 with a compound annual growth rate of 11.75%.
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Q3 2025 Earnings Call Transcript
Operator: Good afternoon. I will be your conference operator today.
BridgeBio Pharma (BBIO) Soars to All-Time High on Stellar Drug Trial Result
BridgeBio rallied for a third straight day on Monday to hit a new all-time high as investors snapped up shares following the stellar results of its final clinical trial for the study of BBP-418 in patients...
UBS Reaffirms Buy on BridgeBio (BBIO) With Optimism Around Attruby Launch
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ranks among the best biotech stocks to buy. UBS reaffirmed its Buy rating for BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BBIO) Retains $68 Target on Strong Launch Dynamics
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is among the most promising biotech stocks to buy according to hedge funds.
7 Most Promising Biotech Stocks to Buy According to Hedge Funds
If there’s one sector that is gaining popularity each day, it’s definitely the biotechnology market.
14 Best Biotech Stocks to Buy Right Now
The biotech industry is almost always buzzing. However, there has been some unanticipated activity in this sector of late.
BridgeBio Pharma's Encaleret Shows Positive Phase 2 Results, Normalizes Calcium in Post-Surgical Hypoparathyroidism
BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the most promising long-term stocks to buy.